Advertisement
ALZN vs VRAX
Which Stock Would AI Choose? Alzamend Neuro (ALZN) vs. Virax Biolabs Group (VRAX) Stock Comparison
Key Takeaways
- ALZN (Alzamend Neuro) is a clinical-stage biopharmaceutical company developing lithium-based and immunotherapy candidates for Alzheimer's disease and psychiatric disorders, with no meaningful revenue.
- VRAX (Virax Biolabs Group) is a biotechnology company focused on immune profiling and in-vitro diagnostics, and has begun converting its technology into commercial supply agreements.
- Both are high-risk, micro-cap healthcare names that have used reverse stock splits and fresh financing to restore Nasdaq listing compliance in recent months.
- VRAX holds a debt-free balance sheet with cash that has recently exceeded its market capitalization and a multi-country commercial supply agreement, while ALZN relies primarily on clinical milestones and analyst coverage.
- Tickeron AI Verdict: VRAX is currently favored for its more concrete near-term commercial catalysts and comparatively stronger liquidity position relative to its market value.
- For more detail, explore ALZN Major News and ALZN Today's Price Move, along with VRAX Major News and VRAX Today's Price Move.
- To see how automated systems evaluate stocks like these in real time, visit the Trending AI Robots page.
Introduction
Investors evaluating small-cap healthcare names often weigh a clinical-stage pipeline against an emerging commercial strategy. That is precisely the trade-off presented by ALZN and VRAX. Both trade on the Nasdaq Capital Market, both carry sub-$10 million market capitalizations, and both have faced listing-compliance and capital-raising challenges in recent periods. Yet their paths diverge sharply: ALZN is betting on Alzheimer's disease drug candidates, while VRAX is monetizing immune-profiling diagnostic technology. This comparison is most relevant to risk-tolerant traders and sector-focused investors tracking relative performance, market positioning, and near-term catalysts among speculative micro-caps.
ALZN Overview and Recent Performance
Alzamend Neuro, Inc. (ALZN) is a clinical-stage biopharmaceutical company advancing AL001, a novel lithium-based formulation targeting Alzheimer's disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder (PTSD), alongside ALZN002, an investigational cell-based therapeutic vaccine. Because the company generates no meaningful revenue, its valuation and share price are driven almost entirely by clinical progress and financing news.
In recent weeks, sentiment has been shaped by several developments. The company regained compliance with Nasdaq's minimum equity requirements after receiving a deficiency notice earlier in the year, and it submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 1/2A trial of ALZN002. Its Phase 1/2A lithium neuroimaging data was also accepted for presentation at a neuroscience conference. Analyst coverage has been supportive, with at least one firm maintaining a Buy rating and a notably higher price target. However, the shares remain volatile and well below their 52-week high, and the company continues to disclose going-concern and funding risks, with negative cash flow and a thin equity base.
VRAX Overview and Recent Performance
Virax Biolabs Group Limited (VRAX) is a biotechnology company developing immune-response detection and T cell immune-profiling technologies. Its core programs include ViraxImmune, a diagnostic platform aimed at post-acute infection syndromes such as Long COVID, and ImmuneSelect, a research-use-only portfolio of peptide pools and immune reagents.
Recent market activity has focused on the company's shift toward commercialization. VRAX signed an exclusive multi-country commercial supply agreement with Fosun Diagnostics covering six Southeast Asian markets, followed by the appointment of three distributors in mainland China. Management has emphasized a debt-free balance sheet, with audited cash of roughly $6.4 million at its fiscal year-end and additional financing raised through preferred option exercises. The company also completed a 1-for-25 reverse stock split and subsequently regained Nasdaq minimum bid price compliance. These catalysts have produced sharp, high-volume price swings, though the shares remain deeply below historical levels and continue to carry meaningful dilution and volatility risk.
Trending AI Robots
Tickeron operates a large ecosystem of AI trading bots that monitor thousands of tickers across different strategies, timeframes, and risk profiles. With hundreds of bots available, each is built around distinct trading styles — from trend-following and breakout models to mean-reversion approaches — and carries its own performance statistics and ticker coverage. Because not every bot suits every market regime, Tickeron curates only the strongest, most appropriate performers into its Trending AI Robots section. This is where traders can review the bots currently generating the most consistent signals under live market conditions and compare their historical metrics side by side. Whether you are evaluating a volatile micro-cap like ALZN or VRAX, exploring the Trending AI Robots page offers a data-driven way to see how automated systems are positioning across the market.
Head-to-Head Comparison
The two companies operate in different corners of healthcare. ALZN is a drug developer whose value hinges on clinical-trial outcomes and regulatory decisions, while VRAX is positioning itself as a commercial diagnostics and immune-profiling provider with early revenue-generating agreements. This difference in business model drives much of their contrasting risk profile.
On momentum, VRAX has delivered more tangible catalysts in recent weeks — a multi-country supply agreement and new distributor relationships — while ALZN's advances are longer-dated, milestone-driven events such as trial initiations and data presentations. On liquidity, VRAX's debt-free status and cash position that has at times exceeded its market capitalization stand in contrast to ALZN's thinner equity base and stated need for additional funding. Sector exposure also differs: ALZN is tied to the competitive and capital-intensive Alzheimer's therapeutic space, whereas VRAX addresses immunology diagnostics with a near-term focus on post-acute infection syndromes.
The trade-offs are clear. ALZN offers potentially larger upside if a clinical catalyst succeeds but carries elevated cash-burn and execution risk. VRAX offers nearer-term commercial traction and a stronger balance sheet relative to valuation, yet its frequent equity raises and reverse split highlight persistent dilution concerns. Neither stock is suited to capital-preservation mandates.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor VRAX in the current environment. The company's combination of a debt-free balance sheet, cash that has recently exceeded its market capitalization, and a signed multi-country commercial supply agreement provides more concrete near-term catalysts and comparatively stronger relative positioning than ALZN's clinical-stage, cash-burning profile. While ALZN's analyst support and pipeline could produce substantial upside if trials succeed, those outcomes remain longer-dated and inherently uncertain. Probabilistically, VRAX's demonstrated commercial momentum and liquidity position make it the more defensible near-term choice — though both names remain speculative and subject to outsized volatility.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALZN is a Hold and VRAX is a StrongBuy.
Momentum Indicator for ALZN turns positive, indicating new upward trend
ALZN saw its Momentum Indicator move above the 0 level on November 03, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned positive. In 72 of the 80 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ALZN just turned positive on October 30, 2026. Looking at past instances where ALZN's MACD turned positive, the stock continued to rise in 32 of 38 cases over the following month. The odds of a continued upward trend are 84%.
Following a +6.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALZN advanced for three days, in 174 of 215 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The 10-day RSI Indicator for ALZN moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 20 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 36 of 38 cases where ALZN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
ALZN moved below its 50-day moving average on November 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ALZN crossed bearishly below the 50-day moving average on October 07, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALZN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ALZN broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALZN entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. ALZN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.173) is normal, around the industry mean (3.498). P/E Ratio (-0.695) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALZN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
VRAX in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 06, 2026
VRAX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 33 cases where VRAX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +10.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where VRAX advanced for three days, in 140 of 172 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VRAX as a result. In 69 of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for VRAX turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 37 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for VRAX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.119) is normal, around the industry mean (3.498). P/E Ratio (-0.649) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (79.365) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. VRAX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VRAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
| ALZN | VRAX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 85% |
| Stochastic ODDS (%) | 2 days ago 90% | N/A |
| Momentum ODDS (%) | 2 days ago 90% | 7 days ago 90% |
| MACD ODDS (%) | 2 days ago 84% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 76% | 2 days ago 90% |
| Advances ODDS (%) | 7 days ago 81% | 14 days ago 81% |
| Declines ODDS (%) | 21 days ago 90% | 2 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 85% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALZN’s FA Score shows that 0 FA rating(s) are green while VRAX’s FA Score has 1 green FA rating(s).
- ALZN’s FA Score: 0 green, 5 red.
- VRAX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALZN’s TA Score shows that 3 TA indicator(s) are bullish while VRAX’s TA Score has 3 bullish TA indicator(s).
- ALZN’s TA Score: 3 bullish, 7 bearish.
- VRAX’s TA Score: 3 bullish, 4 bearish.
Price Growth
ALZN (@Biotechnology) experienced а -7.53% price change this week, while VRAX (@Biotechnology) price change was -39.80% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
ALZN is expected to report earnings on Dec 08, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ALZN and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALZN has been loosely correlated with VRAX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ALZN jumps, then VRAX could also see price increases.
| Ticker / NAME | Correlation To ALZN | 1D Price Change % | ||
|---|---|---|---|---|
| ALZN | 100% | -5.92% | ||
| VRAX - ALZN | 46% Loosely correlated | -9.27% | ||
| FTH - ALZN | 41% Loosely correlated | +1.89% | ||
| ASBP - ALZN | 38% Loosely correlated | +0.06% | ||
| LTRN - ALZN | 36% Loosely correlated | -22.70% | ||
| SILO - ALZN | 33% Loosely correlated | +9.82% | ||
More | ||||
VRAX and
Correlation & Price change
A.I.dvisor indicates that over the last year, VRAX has been loosely correlated with ALZN. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if VRAX jumps, then ALZN could also see price increases.
| Ticker / NAME | Correlation To VRAX | 1D Price Change % | ||
|---|---|---|---|---|
| VRAX | 100% | -9.27% | ||
| ALZN - VRAX | 45% Loosely correlated | -5.92% | ||
| NTRB - VRAX | 31% Poorly correlated | -3.36% | ||
| PTGX - VRAX | 30% Poorly correlated | +0.26% | ||
| CAPR - VRAX | 30% Poorly correlated | -9.95% | ||
| DYAI - VRAX | 29% Poorly correlated | -3.84% | ||
More | ||||